Schedule
Schedule
Switch protocol
Schedule Switch protocol
An upclose photo of a neon sign reading 'fewer doses'. An upclose photo of a neon sign reading 'fewer doses'.

Patients could get HAE control in fewer doses

Schedule

DAWNZERA has the longest dosing option for HAE1

DAWNZERA can give patients control without added complexity

Calendar icon

At-home dosing:
one injection every 4 or 8 weeks1

•

Recommended dose: DAWNZERA 80 mg subcutaneously every 4 weeks1

•

DAWNZERA 80 mg subcutaneously every 8 weeks may also be considered1

If a dose is missed, advise patients to take DAWNZERA as soon as possible and then take their next dose 4 or 8 weeks later, as prescribed.1

Autoinjector icon

Convenient and easy-to-store
autoinjector1,2

•

Only 10 seconds to inject each 0.8 mL dose1

•

Refrigeration is recommended1

•

Can be stored at room temperature up to 86 °F (30 °C) in the original carton for up to 6 weeks1

Personal injection support is available for patients who enroll in the Ionis Every Step™ program or they can watch the DAWNZERA injection training video.

DAWNZERA contains no citric acid—which is
associated with injection-site pain1,3*
*In clinical studies, injection-site reactions, including injection-site pain, were the most frequently reported adverse reactions with DAWNZERA.1
Switch Protocol
14-day protocol to switch to DAWNZERA4*

Consider the time to pharmacologic effect when switching from a different prophylactic therapy to DAWNZERA.1

  1. Start DAWNZERA
  2. Continue taking the current dose of berotralstat for 14 days
  1. Stop taking lanadelumab
  2. Wait 14 days before starting DAWNZERA
  1. Start DAWNZERA
  2. Continue taking the current dose of the C1-INH for 14 days
*Switch protocol used in the OASISplus study.4

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

References: 1. DAWNZERA. Prescribing information. Ionis Pharmaceuticals. 2. Khatri H, Estepa P, Cummings B. Participant reported ease-of-use with a prefilled, single-dose, disposable autoinjector for the treatment of hereditary angioedema. J Allergy Clin Immunol. 2025;155(2 Suppl):AB228. doi:10.1016/j.jaci.2024.12.704. 3. Junker S, Ebert O, Bartsch R. A systematic literature review of injection site pain perception in adult patients treated with citrate-free and citrate-containing biologic agents. Curr Rheumatol Rev. 2023;19(3):303-313. doi:10.2174/1573397118666220829123713 4. Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. 2025 Jul 17:S2213-2198(25)00599-9. doi:10.1016/j.jaip.2025.06.018